Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 3.51
CORT's Cash-to-Debt is ranked lower than
65% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. CORT: 3.51 )
Ranked among companies with meaningful Cash-to-Debt only.
CORT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.72  Med: 871.57 Max: No Debt
Current: 3.51
Equity-to-Asset 0.60
CORT's Equity-to-Asset is ranked lower than
58% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CORT: 0.60 )
Ranked among companies with meaningful Equity-to-Asset only.
CORT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.1  Med: 0.62 Max: 0.9
Current: 0.6
-0.1
0.9
Interest Coverage 4.99
CORT's Interest Coverage is ranked lower than
90% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CORT: 4.99 )
Ranked among companies with meaningful Interest Coverage only.
CORT' s Interest Coverage Range Over the Past 10 Years
Min: 4.99  Med: N/A Max: No Debt
Current: 4.99
Piotroski F-Score: 8
Altman Z-Score: 19.43
Beneish M-Score: -2.45
WACC vs ROIC
8.74%
223.16%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 12.52
CORT's Operating Margin % is ranked higher than
82% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. CORT: 12.52 )
Ranked among companies with meaningful Operating Margin % only.
CORT' s Operating Margin % Range Over the Past 10 Years
Min: -69827.59  Med: -748.74 Max: 12.52
Current: 12.52
-69827.59
12.52
Net Margin % 10.01
CORT's Net Margin % is ranked higher than
81% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. CORT: 10.01 )
Ranked among companies with meaningful Net Margin % only.
CORT' s Net Margin % Range Over the Past 10 Years
Min: -69537.93  Med: -797.39 Max: 10.01
Current: 10.01
-69537.93
10.01
ROE % 29.72
CORT's ROE % is ranked higher than
96% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. CORT: 29.72 )
Ranked among companies with meaningful ROE % only.
CORT' s ROE % Range Over the Past 10 Years
Min: -356.04  Med: -110.44 Max: 29.72
Current: 29.72
-356.04
29.72
ROA % 13.87
CORT's ROA % is ranked higher than
93% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. CORT: 13.87 )
Ranked among companies with meaningful ROA % only.
CORT' s ROA % Range Over the Past 10 Years
Min: -106.94  Med: -73.98 Max: 13.87
Current: 13.87
-106.94
13.87
ROC (Joel Greenblatt) % 468.09
CORT's ROC (Joel Greenblatt) % is ranked higher than
98% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. CORT: 468.09 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CORT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -370585.71  Med: -40045.6 Max: 468.09
Current: 468.09
-370585.71
468.09
3-Year Revenue Growth Rate 88.80
CORT's 3-Year Revenue Growth Rate is ranked higher than
93% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. CORT: 88.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CORT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 230.2
Current: 88.8
0
230.2
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CORT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CORT Guru Trades in Q1 2016

First Eagle Investment 395,670 sh (+31.89%)
Paul Tudor Jones 28,799 sh (+6.27%)
Joel Greenblatt Sold Out
Jim Simons 191,400 sh (-58.43%)
» More
Q2 2016

CORT Guru Trades in Q2 2016

Joel Greenblatt 15,024 sh (New)
Jim Simons 310,600 sh (+62.28%)
Paul Tudor Jones 28,449 sh (-1.22%)
First Eagle Investment 223,935 sh (-43.40%)
» More
Q3 2016

CORT Guru Trades in Q3 2016

Jim Simons 560,000 sh (+80.30%)
Joel Greenblatt 20,908 sh (+39.16%)
Paul Tudor Jones 23,564 sh (-17.17%)
First Eagle Investment 125,000 sh (-44.18%)
» More
Q4 2016

CORT Guru Trades in Q4 2016

Jim Simons 1,507,500 sh (+169.20%)
Joel Greenblatt 38,010 sh (+81.80%)
Paul Tudor Jones Sold Out
First Eagle Investment Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CORT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:GNFTF, NAS:FOLD, NAS:EPZM, NAS:INSM, NAS:ALDR, NAS:FPRX, OTCPK:PFSCF, NAS:CHRS, NAS:AIMT, NAS:XNCR, NAS:ASND, NAS:LOXO, OTCPK:MEOBF, NYSE:EBS, NAS:ZIOP, NAS:FWP, OTCPK:BPMUF, NAS:JNCE, NAS:RGEN, NAS:GBT » details
Traded in other countries:HTD.Germany,
Headquarter Location:USA
Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

Corcept Therapeutics Inc was incorporated in the State of Delaware on May 13, 1998. The Company is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric and oncologic disorders. The Company focuses on disorders associated with the steroid hormone cortisol. The company focuses on commercializing Korlym 300 mg Tablet, a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It is also conducting a Phase III clinical study for mifepristone, the active ingredient in Korlym, for the treatment of psychotic depression; and developing CORT 108297, a novel glucocorticoid receptor II antagonist in Phase 1b/2a clinical trial. The Company has research and development agreement with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone.

Top Ranked Articles about Corcept Therapeutics Inc

Corcept Therapeutics Appoints Renee D. Gala to Board of Directors

MENLO PARK, CA--(Marketwired - Jun 28, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, psychiatric and oncologic disorders by modulating the effects of the stress hormone cortisol, announced today that Renée D. Galá has joined the company's Board of Directors. "I am very pleased to welcome Renée to our Board," said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. "Her broad financial and operating experience will be invaluable as we continue to grow our Cushing's syndrome business and advance our portfolio of cortisol-modulating compounds for new indications." Ms. Galá is the Senior Vice President and Chief Financial Officer of Theravance Biopharma, a public biopharmaceutical company focused on anti-infectives and diseases of the lung and gastrointestinal tract. In that role, she is responsible for finance, accounting, tax, investor relations, information technology, facilities and corporate business development. Ms. Galá joined Theravance, Inc. in 2006 and held various roles in the finance organization before leading the separation of the biopharmaceutical business (now Theravance Biopharma) from the royalty company (Innoviva, Inc.) in 2014. Prior to joining Theravance, Inc., Ms. Galá held positions of increasing responsibility in global treasury, pharmaceutical sales, and corporate strategy/business development at Eli Lilly and Company. Before that, she worked for seven years in the energy industry, both in the United States and internationally, in positions focused on corporate finance, project finance and mergers and acquisitions. Ms. Galá holds a B.S. in Mathematics from Vanderbilt University and an M.B.A. from Columbia Business School. "I am excited to join the Corcept team," said Ms. Galá. "The company's Cushing's syndrome franchise is a promising stand-alone business that also supports development of cortisol modulators with demonstrated therapeutic potential. In the next 12-18 months, research conducted by Corcept and its academic collaborators will generate efficacy data in a wide range of serious disorders. I am looking forward to contributing to the advancement of such a broad and rich therapeutic platform." About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol. Korlym®, a first-generation cortisol modulator, is the company's first FDA-approved medication. The company has a portfolio of proprietary compounds that selectively modulate the effects of cortisol but not progesterone. Corcept owns extensive intellectual property covering the use of cortisol modulators, including mifepristone (the active ingredient in Korlym), in the treatment of a wide variety of serious disorders. It also holds composition of matter patents covering its selective cortisol modulators. Forward-Looking Statements
Statements made in this press release, other than statements of historical fact, are forward-looking statements. These forward-looking statements, including statements regarding the timing of clinical trial results and the advancement of the company's therapeutic platform, are subject to known and unknown risks and uncertainties that might cause actual results to differ materially from those expressed or implied by such statements, including the pace of Korlym's acceptance by physicians and patients, the pace of enrollment in or the outcome of Corcept's Phase 1/2 study of mifepristone in the treatment of triple-negative breast cancer, CORT125134 to treat solid-tumor cancers and clinical trials being undertaken by academic investigators at the University of Chicago and elsewhere, the pre-clinical development of Corcept's selective cortisol modulators, the effects of rapid technological change and competition, the protections afforded by Korlym's Orphan Drug designation or Corcept's intellectual property rights, or the cost, pace and success of Corcept's other product development efforts. These and other risks are set forth in the company's SEC filings, which are available at the company's website (corcept.com) or from the SEC's website (sec.gov). Corcept disclaims any intention or duty to update any forward-looking statement made in this press release.


CONTACT:

Charles Robb

Chief Financial Officer

Corcept Therapeutics

650-688-8783

Email Contact

www.corcept.com





Read more...
Corcept Therapeutics Provides Update of Progress in Cortisol Modulation Oncology Program

MENLO PARK, CA--(Marketwired - Jun 2, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT)

Preliminary efficacy results in Phase 1/2 trial of mifepristone plus eribulin (Eisai's Halaven®) to treat triple-negative breast cancer (TNBC) indicate combination is active; final results expected in mid-2016



First patient enrolled in Phase 1/2 trial of selective cortisol modulator CORT125134 plus nab-paclitaxel (Celgene's Abraxane®) to treat a range of solid-tumor cancers



First patient enrolled in University of Chicago Phase 2 trial of mifepristone plus enzalutamide (Medivation's Xtandi®) to treat metastatic, castration-resistant prostate cancer (CRPC)



The University of Chicago to conduct a Phase 2 trial, supported by Celgene Corporation and Corcept Therapeutics, of mifepristone plus Abraxane to treat patients with TNBC





Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, psychiatric and oncologic disorders by modulating the effects of the stress hormone cortisol, released preliminary efficacy data from its Phase 1/2 trial of mifepristone to treat patients with metastatic (TNBC). The company also provided an update of developments in other clinical trials of cortisol modulators, including mifepristone, to treat a variety of solid-tumor cancers. "Preliminary data from our Phase 1/2 trial in patients with TNBC support our hypothesis that cortisol modulators such as mifepristone augment standard chemotherapy in difficult to treat solid-tumor cancers," said Joseph K. Belanoff, MD, Corcept's Chief Executive Officer. "We look forward to the trial's final results, which will guide us as we advance our oncology programs." "It's exciting to see the study of cortisol modulation as a treatment for GR-positive solid-tumor cancers advance so broadly," said Robert S. Fishman, MD, Corcept's Chief Medical Officer. "In addition to our trial combining mifepristone and Halaven, we have begun dosing patients in a Phase 1/2 trial combining our proprietary cortisol modulator, CORT125134, with Abraxane. Our colleagues at the University of Chicago are also taking important steps to explore cortisol modulation's potential in oncology. They have begun enrolling patients in a Phase 2 trial of mifepristone plus Xtandi to treat CRPC. In the coming months, they plan to start a controlled Phase 2 study, with support from Celgene and Corcept, of mifepristone in combination with Abraxane to treat patients with TNBC." Preliminary Results in Corcept's Phase 1/2 Trial of Mifepristone to Treat TNBC This open-label trial is investigating whether the addition of mifepristone enhances the effect of Halaven in patients with TNBC whose tumors express the glucocorticoid receptor (GR), one of the receptors to which mifepristone binds. The trial has enrolled 21 patients with GR-positive tumors and two with tumors whose GR status is not currently known. As determined using the Response Evaluation Criteria in Solid Tumors (RECIST), preliminary efficacy results in this group were as follows: Three patients exhibited a partial response, defined as a 30 percent or greater reduction in tumor size, eight had stable disease and 11 had progressive disease. One patient is too early in treatment to be assessed (see Figure 1). "These preliminary data are encouraging," said Dr. Fishman. "For example, five patients achieved progression-free survival (PFS) longer than the upper bound for PFS in TNBC patients receiving Halaven monotherapy in a comparable population (Aogi et al., Annals of Oncology 23: 1441-1448, 2012). We expect our analysis of the complete, final data will tell us more." The combination of mifepristone and Halaven has been well-tolerated. Neutropenia has been manageable with the administration of growth factor. Other adverse events have been mainly of mild or moderate severity, with the most common being fatigue, nausea, hypokalemia, hair loss and neuropathy. Final results are expected in mid-2016. Corcept's Phase 1/2 Trial of CORT125134 to Treat Solid-Tumor Cancers Corcept has begun dosing patients in a trial of its proprietary, selective cortisol modulator, CORT125134, together with Abraxane to treat solid-tumor cancers (clinicaltrials.gov identifier NCT02012296). The trial's first phase will identify a recommended dose of Abraxane and CORT125134. The second phase will test the combination's efficacy against a range of tumor types in one or more 20-patient cohorts. Possible target indications include TNBC, CRPC, ovarian cancer, pancreatic cancer and sarcoma. Other cohorts may be enrolled to study CORT125134 with different companion agents, including PD-1 inhibitors. In animal models, the addition of CORT125134 to PD-1 monotherapy significantly slowed tumor progression relative to PD-1 monotherapy. (For more information, see the company's press release of April 28, 2016 at corcept.com.) Initial results are expected in 2017. University of Chicago Two Phase 2 Trials of Mifepristone to Treat CRPC and TNBC Researchers at the University of Chicago have begun enrolling patients in the Phase 2 portion of their trial of mifepristone combined with Xtandi to treat patients with metastatic CRPC (clinicaltrials.gov identifier NCT02012296). The University of Chicago investigators are also planning to conduct a placebo-controlled, double-blind, Phase 2 trial of mifepristone combined with Abraxane to treat patients with advanced, GR-positive TNBC (clinicaltrials.gov identifier NCT02788981). Celgene is providing support for the Abraxane/mifepristone trial. The Department of Defense and the Prostate Cancer/Movember Foundation are providing support for the CRPC trial. Corcept is providing mifepristone to both the TNBC and CRPC trials. Corcept has licensed patents from the University of Chicago covering the use of cortisol modulators in combination with anti-cancer agents to treat TNBC and CRPC. About TNBC TNBC is a form of breast cancer in which the three receptors that fuel most breast cancer growth -- estrogen, progesterone and HER-2 -- are not present. Because the tumor cells lack these receptors, treatments that target estrogen, progesterone and HER-2 are ineffective. Approximately 40,000 women are diagnosed with triple-negative breast cancer each year. It is estimated that more than 75 percent of these women's tumor cells express GR. There is no FDA-approved treatment and neither a targeted treatment nor an approved standard chemotherapy regimen for relapsed triple-negative breast cancer patients exists. Corcept has licensed patents from the University of Chicago covering the use of GR antagonists in combination with chemotherapy to treat TNBC and castration-resistant prostate cancer. About CRPC Castration-resistant prostate cancer (CRPC) is a form of the disease that progresses despite androgen receptor blockade. There are approximately 130,000 patients with metastatic CRPC in the United States. The prognosis for patients with metastatic disease is poor. About Mifepristone Mifepristone is the active ingredient in Corcept's product, Korlym® 300mg tablets, which the FDA has approved for the once-daily oral treatment of hyperglycemia secondary to endogenous Cushing's syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. Korlym (mifepristone) ameliorates the symptoms of Cushing's syndrome by modulating the activity of cortisol at GR, one of the two receptors to which cortisol binds. Korlym was the first FDA-approved treatment for that illness and the FDA has designated it as an Orphan Drug for that indication. About CORT125134 CORT125134 is the lead compound in Corcept's portfolio of selective cortisol modulators. It is a non-steroidal competitive antagonist of GR that does not bind to the body's other hormone receptors, including the progesterone receptor. It is the affinity of Korlym for the progesterone receptor that results in termination of pregnancy and can cause endometrial thickening and irregular vaginal bleeding in some women. CORT125134 will not have these effects. The compound is proprietary to Corcept and is protected by composition of matter and method of use patents extending into 2033. About Corcept Therapeutics Incorporated Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym, a first-generation cortisol modulator, is the company's first FDA-approved medication. The company has a portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive intellectual property covering the use of cortisol modulators, including mifepristone, in the treatment of a wide variety of metabolic, oncologic and psychiatric disorders. It also holds composition of matter patents covering its selective cortisol modulators. Forward-Looking Statements Statements made in this press release, other than statements of historical fact, are forward-looking statements. These forward-looking statements, including statements regarding anticipated future net revenues, the timing of clinical trials and clinical trial results and the advancement of clinical trials, are subject to known and unknown risks and uncertainties that might cause actual results to differ materially from those expressed or implied by such statements, including the pace of enrollment in or the outcome of the Corcept's Phase 1/2 study of mifepristone in the treatment of TNBC, CORT125134 to treat solid-tumor cancers and clinical trials being undertaken by academic investigators at the University of Chicago, the pace of enrollment the effects of rapid technological change and competition, the protections afforded by Corcept's intellectual property rights, or the cost, pace and success of Corcept's other product development efforts. These and other risks are set forth in the company's SEC filings, which are available at the company's website (corcept.com) or from the SEC's website (sec.gov). Corcept disclaims any intention or duty to update any forward-looking statement made in this press release. Abraxane® is a registered trademark of Celgene Corporation. Halaven® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Company, Ltd. Xtandi® is a registered trademark of Astellas Pharma Inc. Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=3016978




CONTACT:

Charles Robb

Chief Financial Officer

Corcept Therapeutics

650-688-8783

Email Contact

www.corcept.com





Read more...

Ratios

vs
industry
vs
history
PE Ratio 136.29
CORT's PE Ratio is ranked lower than
93% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. CORT: 136.29 )
Ranked among companies with meaningful PE Ratio only.
CORT' s PE Ratio Range Over the Past 10 Years
Min: 103.71  Med: 155.9 Max: 601
Current: 136.29
103.71
601
PE Ratio without NRI 136.29
CORT's PE Ratio without NRI is ranked lower than
91% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. CORT: 136.29 )
Ranked among companies with meaningful PE Ratio without NRI only.
CORT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 103.71  Med: 155.9 Max: 601
Current: 136.29
103.71
601
Price-to-Owner-Earnings 119.25
CORT's Price-to-Owner-Earnings is ranked lower than
83% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. CORT: 119.25 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CORT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 68.08  Med: 115.79 Max: 667.78
Current: 119.25
68.08
667.78
PB Ratio 25.99
CORT's PB Ratio is ranked lower than
96% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CORT: 25.99 )
Ranked among companies with meaningful PB Ratio only.
CORT' s PB Ratio Range Over the Past 10 Years
Min: 1.82  Med: 14.28 Max: 86.18
Current: 25.99
1.82
86.18
PS Ratio 13.46
CORT's PS Ratio is ranked lower than
56% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CORT: 13.46 )
Ranked among companies with meaningful PS Ratio only.
CORT' s PS Ratio Range Over the Past 10 Years
Min: 7.18  Med: 136.52 Max: 1990
Current: 13.46
7.18
1990
Price-to-Free-Cash-Flow 60.00
CORT's Price-to-Free-Cash-Flow is ranked lower than
79% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. CORT: 60.00 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CORT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 33.4  Med: 61.2 Max: 188.93
Current: 60
33.4
188.93
Price-to-Operating-Cash-Flow 59.63
CORT's Price-to-Operating-Cash-Flow is ranked lower than
84% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. CORT: 59.63 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CORT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 33.19  Med: 60.94 Max: 182.41
Current: 59.63
33.19
182.41
EV-to-EBIT 102.39
CORT's EV-to-EBIT is ranked lower than
92% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CORT: 102.39 )
Ranked among companies with meaningful EV-to-EBIT only.
CORT' s EV-to-EBIT Range Over the Past 10 Years
Min: -160.5  Med: -5.75 Max: 488.9
Current: 102.39
-160.5
488.9
EV-to-EBITDA 101.52
CORT's EV-to-EBITDA is ranked lower than
90% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CORT: 101.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
CORT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -168  Med: -5.75 Max: 436.4
Current: 101.52
-168
436.4
Current Ratio 2.40
CORT's Current Ratio is ranked lower than
68% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CORT: 2.40 )
Ranked among companies with meaningful Current Ratio only.
CORT' s Current Ratio Range Over the Past 10 Years
Min: 2.23  Med: 6.48 Max: 20.96
Current: 2.4
2.23
20.96
Quick Ratio 2.31
CORT's Quick Ratio is ranked lower than
66% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CORT: 2.31 )
Ranked among companies with meaningful Quick Ratio only.
CORT' s Quick Ratio Range Over the Past 10 Years
Min: 2.14  Med: 6.48 Max: 20.96
Current: 2.31
2.14
20.96
Days Inventory 368.33
CORT's Days Inventory is ranked lower than
88% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. CORT: 368.33 )
Ranked among companies with meaningful Days Inventory only.
CORT' s Days Inventory Range Over the Past 10 Years
Min: 355.69  Med: 476.53 Max: 2487.36
Current: 368.33
355.69
2487.36
Days Sales Outstanding 44.25
CORT's Days Sales Outstanding is ranked higher than
65% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CORT: 44.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
CORT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.25  Med: 45.83 Max: 61.48
Current: 44.25
44.25
61.48
Days Payable 406.15
CORT's Days Payable is ranked higher than
91% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. CORT: 406.15 )
Ranked among companies with meaningful Days Payable only.
CORT' s Days Payable Range Over the Past 10 Years
Min: 355.35  Med: 780.49 Max: 15257.8
Current: 406.15
355.35
15257.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.10
CORT's 3-Year Average Share Buyback Ratio is ranked higher than
77% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CORT: -4.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CORT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -61.6  Med: -20.3 Max: -3.2
Current: -4.1
-61.6
-3.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 45.43
CORT's Price-to-Net-Cash is ranked lower than
92% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. CORT: 45.43 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CORT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.55  Med: 8.26 Max: 83
Current: 45.43
2.55
83
Price-to-Net-Current-Asset-Value 28.05
CORT's Price-to-Net-Current-Asset-Value is ranked lower than
92% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. CORT: 28.05 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CORT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.47  Med: 8.14 Max: 35.57
Current: 28.05
2.47
35.57
Price-to-Tangible-Book 25.99
CORT's Price-to-Tangible-Book is ranked lower than
94% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. CORT: 25.99 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CORT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.31  Med: 8.07 Max: 29.47
Current: 25.99
2.31
29.47
Price-to-Median-PS-Value 0.09
CORT's Price-to-Median-PS-Value is ranked higher than
97% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CORT: 0.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CORT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 0.26 Max: 1.85
Current: 0.09
0.07
1.85
Price-to-Graham-Number 12.55
CORT's Price-to-Graham-Number is ranked lower than
93% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. CORT: 12.55 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CORT' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 9.55  Med: 9.55 Max: 12.55
Current: 12.55
9.55
12.55
Earnings Yield (Greenblatt) % 0.98
CORT's Earnings Yield (Greenblatt) % is ranked higher than
71% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CORT: 0.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CORT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 0.8 Max: 1.3
Current: 0.98
0.2
1.3

More Statistics

Revenue (TTM) (Mil) $81.32
EPS (TTM) $ 0.07
Beta1.07
Short Percentage of Float7.63%
52-Week Range $4.60 - 11.58
Shares Outstanding (Mil)113.11
» More Articles for CORT

Headlines

Articles On GuruFocus.com
Corcept Therapeutics Appoints Renee D. Gala to Board of Directors Jun 28 2016 
Corcept Therapeutics Provides Update of Progress in Cortisol Modulation Oncology Program Jun 02 2016 
Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Confe Apr 29 2016 
Promising Pre-Clinical and Phase 1 Data Support Advance of Selective Cortisol Modulator CORT125134 a Apr 28 2016 
David Swensen Bets on Antero Resources Mar 10 2016 
Corcept Therapeutics Announces Preliminary Fourth Quarter and Full Year 2015 Summary Financial Resul Jan 28 2016 
Corcept Therapeutics to Announce Preliminary 2015 Financial Results, Provide 2016 Revenue Guidance a Jan 21 2016 
Corcept Therapeutics Announces Initial Efficacy Results in Phase 1/2 Trial of Mifepristone in Combin Dec 14 2015 
Corcept Therapeutics to Announce Third Quarter Financial Results and Corporate Update and Host Confe Oct 29 2015 
Results of Phase 1 Trial of Next-Generation Cortisol Modulator CORT125134 to Be Presented at Annual Oct 13 2015 

More From Other Websites
Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View Apr 27 2017
Corcept Therapeutics, Inc. – Value Analysis (NASDAQ:CORT) : April 25, 2017 Apr 25 2017
Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host... Apr 24 2017
Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : April... Apr 24 2017
Here's Why Corecept Therapeutics Incorporated Had a Rough Day Apr 21 2017
Nivalis' (NVLS) Shares Down After Merger Deal with Alpine Apr 20 2017
Corcept (CORT) Up 18% Since Earnings Report: Can It Continue? Apr 06 2017
Corcept (CORT) Strives to Commercialize Key Drug Korlym Mar 29 2017
Corcept Therapeutices Eyes Another Double Mar 20 2017
Today's Research Reports on Stocks to Watch: Array Biopharma and Corcept Therapeutics Mar 17 2017
Under-The-Radar Biotech Tests Buy Zone; Cancer Trial Results 'Encouraging' Mar 10 2017
Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
Corcept beats 4Q profit forecasts Mar 06 2017
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results; Increases 2017... Mar 06 2017
Corcept Therapeutics, Inc. – Value Analysis (NASDAQ:CORT) : February 14, 2017 Feb 14 2017
Edited Transcript of CORT earnings conference call or presentation 30-Jan-17 10:00pm GMT Jan 31 2017
Corcept Therapeutics Announces Preliminary Fourth Quarter and Full-Year 2016 Financial Results and... Jan 30 2017
Corcept Therapeutics to Announce Preliminary 2016 Financial Results, Provide 2017 Revenue Guidance... Jan 23 2017
Corcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US :... Jan 11 2017
3 Stocks Expected to More Than Double Their Earnings in 2017 Jan 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)